CA2290966A1 - Sertraline salts and sustained-release dosage forms of sertraline - Google Patents
Sertraline salts and sustained-release dosage forms of sertraline Download PDFInfo
- Publication number
- CA2290966A1 CA2290966A1 CA002290966A CA2290966A CA2290966A1 CA 2290966 A1 CA2290966 A1 CA 2290966A1 CA 002290966 A CA002290966 A CA 002290966A CA 2290966 A CA2290966 A CA 2290966A CA 2290966 A1 CA2290966 A1 CA 2290966A1
- Authority
- CA
- Canada
- Prior art keywords
- sertraline
- dosage forms
- salt
- mga
- sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Abstract
Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr. The present invention is further directed to an acetate salt, an L-lactate salt and an L-aspartate salt of sertraline, pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed to processes for preparing sertraline acetate, sertraline L-lactate and sertraline L-aspartate.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5142097P | 1997-07-01 | 1997-07-01 | |
US5140297P | 1997-07-01 | 1997-07-01 | |
US5141497P | 1997-07-01 | 1997-07-01 | |
US5149897P | 1997-07-01 | 1997-07-01 | |
US60/051,402 | 1997-07-01 | ||
US60/051,498 | 1997-07-01 | ||
US60/051,414 | 1997-07-01 | ||
US60/051,420 | 1997-07-01 | ||
PCT/IB1998/000934 WO1999001121A1 (en) | 1997-07-01 | 1998-06-15 | Sertraline salts and sustained-release dosage forms of sertraline |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2290966A1 true CA2290966A1 (en) | 1999-01-14 |
CA2290966C CA2290966C (en) | 2005-12-20 |
Family
ID=27489408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002290966A Expired - Fee Related CA2290966C (en) | 1997-07-01 | 1998-06-15 | Sertraline salts and sustained-release dosage forms of sertraline |
Country Status (33)
Country | Link |
---|---|
US (1) | US6517866B1 (en) |
EP (1) | EP0999830A1 (en) |
JP (1) | JP2000514101A (en) |
KR (2) | KR100446366B1 (en) |
CN (1) | CN1256085C (en) |
AP (1) | AP1526A (en) |
AR (2) | AR015919A1 (en) |
AU (1) | AU739261B2 (en) |
BG (1) | BG103915A (en) |
BR (1) | BR9810403A (en) |
CA (1) | CA2290966C (en) |
CO (1) | CO4940402A1 (en) |
DZ (1) | DZ2546A1 (en) |
EA (1) | EA002482B1 (en) |
HK (1) | HK1026630A1 (en) |
HR (1) | HRP980379B1 (en) |
HU (1) | HUP0002296A3 (en) |
ID (1) | ID23503A (en) |
IL (2) | IL133080A0 (en) |
IS (1) | IS5265A (en) |
MY (1) | MY129175A (en) |
NO (1) | NO996518L (en) |
NZ (2) | NZ501251A (en) |
OA (1) | OA11245A (en) |
PA (1) | PA8454401A1 (en) |
PE (1) | PE88699A1 (en) |
PL (1) | PL337806A1 (en) |
SK (1) | SK180499A3 (en) |
TN (1) | TNSN98125A1 (en) |
TR (1) | TR199903280T2 (en) |
TW (1) | TWI241188B (en) |
UY (1) | UY25067A1 (en) |
WO (1) | WO1999001121A1 (en) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040208926A1 (en) * | 1997-07-01 | 2004-10-21 | Pfizer Inc | Solubilized sertraline compositions |
JP4533531B2 (en) * | 1998-04-03 | 2010-09-01 | ビーエム リサーチ エイ/エス | Controlled release composition |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
EP1852111A1 (en) * | 1999-05-20 | 2007-11-07 | ELAN CORPORATION, Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
IE990406A1 (en) | 1999-05-20 | 2000-12-27 | Elan Corp Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. |
SI1225881T1 (en) | 1999-09-03 | 2006-06-30 | Apbi Holdings Llc | The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction |
GB9923045D0 (en) * | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
BR0016707A (en) | 1999-12-23 | 2002-09-03 | Pfizer Prod Inc | Hydrogel-driven layered drug dosage form |
US6620431B1 (en) * | 2000-04-17 | 2003-09-16 | Charles Signorino | Shellac film coatings providing release at selected pH and method |
US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
JP2004507502A (en) | 2000-08-30 | 2004-03-11 | ファイザー・プロダクツ・インク | Sustained release formulation for growth hormone secretagogue |
US6482440B2 (en) * | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
SE0004671D0 (en) | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
JP2002212062A (en) * | 2001-01-24 | 2002-07-31 | Teijin Ltd | Composition for controlling delayed delease |
US20040076682A1 (en) * | 2001-02-15 | 2004-04-22 | Toshiyuki Kohzaki | Novel ophthalmic compositions |
EP1385486A4 (en) * | 2001-04-18 | 2006-05-17 | Nostrum Pharmaceuticals Inc | A novel coating for a sustained release pharmaceutical composition |
PL367686A1 (en) * | 2001-07-16 | 2005-03-07 | Astrazeneca Ab | Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
US20040234602A1 (en) * | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
JP2005509605A (en) * | 2001-09-28 | 2005-04-14 | マクニール−ピーピーシー・インコーポレイテッド | A dosage form comprising an edible composition and an edible skin |
US7005138B2 (en) * | 2001-12-21 | 2006-02-28 | Duramed Pharmaceuticals, Inc. | Method of systematically delivering SSRIs |
US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
US20100189797A1 (en) | 2002-06-10 | 2010-07-29 | Julien Mendlewicz | Oral antidepressant formulation |
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
AU2003272461A1 (en) * | 2002-09-16 | 2004-04-30 | Sepracor Inc. | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE |
US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
CA2415154C (en) * | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
WO2004065348A1 (en) * | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
AU2004212919A1 (en) * | 2003-02-14 | 2004-09-02 | Combinatorx, Incorporated | Combination therapy for the treatment of immunoinflammatory disorders |
ES2360102T3 (en) | 2003-03-26 | 2011-05-31 | Egalet A/S | SYSTEM FOR CONTROLLED RELEASE OF MORPHINE. |
WO2004087175A1 (en) * | 2003-04-04 | 2004-10-14 | Pharmacia Corporation | Oral extended release compressed tablets of multiparticulates |
RU2391093C2 (en) | 2003-04-24 | 2010-06-10 | Джаготек Аг | Slow-release tablet with specified core geometry |
WO2005000786A1 (en) * | 2003-05-23 | 2005-01-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
ATE454138T1 (en) * | 2003-08-08 | 2010-01-15 | Biovail Lab Int Srl | MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE |
JP4791970B2 (en) * | 2003-11-04 | 2011-10-12 | シプラ・リミテッド | Process for producing polymorphs of selective serotonin reuptake inhibitors |
TW200539903A (en) * | 2004-03-12 | 2005-12-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
KR100772980B1 (en) * | 2004-04-01 | 2007-11-02 | 한미약품 주식회사 | Controlled release formulation for oral administration of metformin |
US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
ITMI20041295A1 (en) * | 2004-06-25 | 2004-09-25 | Cosmo Spa | ORAL ANTI-MICROBIAL PHARMACEUTICAL COMPOSITIONS |
RS51527B2 (en) | 2004-08-13 | 2018-02-28 | Boehringer Ingelheim Int | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
KR100920856B1 (en) * | 2004-11-30 | 2009-10-09 | (주)아모레퍼시픽 | Extended-release preparation containing selective serotonin reuptake inhibitor and process for the preparation thereof |
WO2006072878A1 (en) * | 2005-01-07 | 2006-07-13 | Ranbaxy Laboratories Limited | Oral dosage forms of sertraline having controlled particle size and processes for their preparation |
US20080274183A1 (en) * | 2005-02-04 | 2008-11-06 | Phillip Michael Cook | Thermoplastic articles containing a medicament |
WO2006123364A2 (en) * | 2005-03-14 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative |
CA2611081C (en) * | 2005-06-03 | 2016-05-31 | Egalet A/S | A drug delivery system for delivering active substances dispersed in a dispersion medium |
US8747897B2 (en) * | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
US7893053B2 (en) * | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
CA2655682A1 (en) | 2006-08-03 | 2008-02-07 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
NZ577560A (en) * | 2007-01-16 | 2012-01-12 | Egalet Ltd | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
WO2009034431A2 (en) | 2007-09-10 | 2009-03-19 | Pfizer Inc. | Controlled-release dosage forms for varenicline |
CA2734095A1 (en) * | 2008-08-14 | 2010-02-18 | Bioneer A/S | Coated tablets with a remaining degradation surface over the time |
DE102008051572A1 (en) | 2008-09-05 | 2010-03-11 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Preparation of phosphate binders and phosphate binders prepared in this way |
AU2008243202B2 (en) * | 2008-11-11 | 2015-08-20 | Cosmo Technologies Ltd | Oral antimicrobial pharmaceutical compositions |
NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
AU2010314994B2 (en) | 2009-11-09 | 2016-10-06 | Spotlight Technology Partners Llc | Fragmented hydrogels |
WO2011057131A1 (en) | 2009-11-09 | 2011-05-12 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
EP2877161A1 (en) | 2012-07-06 | 2015-06-03 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
JP6041823B2 (en) | 2013-03-16 | 2016-12-14 | ファイザー・インク | Tofacitinib oral sustained release dosage form |
WO2016020936A2 (en) * | 2014-07-21 | 2016-02-11 | Patel Jayendrakumar Dasharathlal | A novel oral gastroretentive pharmaceutical dosage form |
CN104402705B (en) * | 2014-11-04 | 2017-04-12 | 成都理工大学 | Spherical calcium citrate, and preparation method and application thereof |
JP6455293B2 (en) * | 2015-04-21 | 2019-01-23 | ニプロ株式会社 | Formulation containing sertraline and / or a pharmaceutically acceptable salt thereof |
MX2020003854A (en) * | 2017-10-05 | 2020-11-13 | Purac Biochem Bv | Lactate powder and method for the preparation thereof. |
CN109432038A (en) * | 2018-12-28 | 2019-03-08 | 乐普制药科技有限公司 | A kind of enteric coated tablet and preparation method thereof containing sertraline hydrochloride |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
DK150008C (en) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION |
US4847092A (en) | 1985-11-12 | 1989-07-11 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
US4797286A (en) | 1985-11-12 | 1989-01-10 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
US5112619A (en) | 1985-11-12 | 1992-05-12 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulation |
US4803076A (en) | 1986-09-04 | 1989-02-07 | Pfizer Inc. | Controlled release device for an active substance |
DE3700420A1 (en) * | 1986-12-22 | 1988-07-07 | Efka Werke Kiehn Gmbh Fritz | TOBACCO PRODUCT FOR THE MANUFACTURE OF A CIGARETTE, IN PARTICULAR FILTER CIGARETTE |
US5135947A (en) | 1987-04-09 | 1992-08-04 | Eli Lilly And Company | 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors |
US4839104A (en) | 1987-06-11 | 1989-06-13 | Pfizer, Inc. | Process for preparing sertraline intermediates |
US4777288A (en) | 1987-06-11 | 1988-10-11 | Pfizer Inc. | Process for preparing a 4,4-diphenylbutanoic acid derivative |
US4792448A (en) | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
US4971998A (en) | 1987-10-22 | 1990-11-20 | Massachusetts Institute Of Technology | Methods for treating the premenstrual or late luteal phase syndrome |
US4876282A (en) | 1987-11-25 | 1989-10-24 | Eli Lilly And Company | 1-Phenylalkylamines as selective serotonin uptake inhibitors |
US4855500A (en) | 1988-05-04 | 1989-08-08 | Pfizer Inc. | Process for preparing a ketimine |
US5026707A (en) | 1988-05-23 | 1991-06-25 | Eli Lilly And Company | Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
IL91398A (en) * | 1988-08-30 | 1994-05-30 | Pfizer | Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane |
ZA901277B (en) | 1989-02-27 | 1991-10-30 | Lilly Co Eli | Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes |
US4981870A (en) | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
US4983401A (en) | 1989-05-22 | 1991-01-08 | Kinaform Technology, Inc. | Sustained release pharmaceutical preparations having pH controlled membrane coatings |
US5130338A (en) | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
EP0415612B1 (en) | 1989-08-30 | 1993-11-10 | Pfizer Inc. | Use of sertraline for the treatment of chemical dependencies |
US4940731A (en) | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
US4962128A (en) | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
WO1992000103A1 (en) | 1990-06-28 | 1992-01-09 | Beecham Group Plc | Pharmaceutical preparations |
JPH0794379B2 (en) | 1990-08-07 | 1995-10-11 | ファイザー・インコーポレーテッド | Methods of using interfacial polymerized membranes in release formulations |
WO1992002215A1 (en) | 1990-08-09 | 1992-02-20 | Massachusetts Institute Of Technology | Method for treating the premenstrual or late luteal phase syndrome |
US5104899A (en) | 1990-08-13 | 1992-04-14 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
JPH06502854A (en) | 1990-11-24 | 1994-03-31 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | Use of paroxetine to treat senile dementia, bulimia, migraines or anorexia |
DE69218813T2 (en) | 1991-02-08 | 1997-08-14 | Lilly Co Eli | Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
AU1919592A (en) | 1991-04-16 | 1992-11-17 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
US5196607A (en) | 1992-02-14 | 1993-03-23 | Pfizer Inc. | Process for preparing ketone enantiomer |
ES2124303T3 (en) | 1992-03-25 | 1999-02-01 | Depomed Inc | DOSAGE FORMS OF DELAYED DELIVERY ORAL DRUGS BASED ON HYDROXYETHYL CELLULOSE. |
US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
US6440457B1 (en) | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
IE930485A1 (en) | 1993-06-28 | 1994-12-28 | Hemisphere Ltd | Antidepressant agents with a rapid onset of action |
US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
ATE214276T1 (en) | 1994-09-19 | 2002-03-15 | Du Pont Pharm Co | COMPOSITIONS OF OPIOID ANTAGONISTS WITH SELECTIVE SEROTONIN UPtake INHIBITORS, FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE |
DK0768083T3 (en) | 1995-07-17 | 2003-06-23 | Pfizer | Use of sertraline to treat patients with post myocardial infarction |
GB9514842D0 (en) | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
CN1146421C (en) | 1996-03-25 | 2004-04-21 | 伊莱利利公司 | Method for treating pain |
ZA97976B (en) | 1996-04-05 | 1997-08-18 | Alza Corp | Uniform drug delivery theraphy. |
US5741807A (en) | 1996-09-27 | 1998-04-21 | Cytos Pharmaceuticals, L.P. | Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas |
US6590083B1 (en) | 1999-04-16 | 2003-07-08 | Ortho-Mcneil Pharmaceutical, Inc. | Ketolide antibacterials |
-
1998
- 1998-06-15 CN CNB988066963A patent/CN1256085C/en not_active Expired - Fee Related
- 1998-06-15 SK SK1804-99A patent/SK180499A3/en unknown
- 1998-06-15 BR BR9810403-9A patent/BR9810403A/en not_active Application Discontinuation
- 1998-06-15 IL IL13308098A patent/IL133080A0/en unknown
- 1998-06-15 PL PL98337806A patent/PL337806A1/en unknown
- 1998-06-15 CA CA002290966A patent/CA2290966C/en not_active Expired - Fee Related
- 1998-06-15 KR KR10-2003-7002633A patent/KR100446366B1/en not_active IP Right Cessation
- 1998-06-15 EP EP98923020A patent/EP0999830A1/en not_active Withdrawn
- 1998-06-15 IL IL15233098A patent/IL152330A0/en unknown
- 1998-06-15 NZ NZ501251A patent/NZ501251A/en unknown
- 1998-06-15 WO PCT/IB1998/000934 patent/WO1999001121A1/en active Application Filing
- 1998-06-15 JP JP11506775A patent/JP2000514101A/en active Pending
- 1998-06-15 HU HU0002296A patent/HUP0002296A3/en unknown
- 1998-06-15 AU AU75449/98A patent/AU739261B2/en not_active Ceased
- 1998-06-15 ID IDW991704A patent/ID23503A/en unknown
- 1998-06-15 US US09/380,897 patent/US6517866B1/en not_active Expired - Fee Related
- 1998-06-15 KR KR10-1999-7012073A patent/KR100412327B1/en not_active IP Right Cessation
- 1998-06-15 TR TR1999/03280T patent/TR199903280T2/en unknown
- 1998-06-15 EA EA199900964A patent/EA002482B1/en not_active IP Right Cessation
- 1998-06-15 NZ NZ513456A patent/NZ513456A/en unknown
- 1998-06-25 TW TW087110253A patent/TWI241188B/en not_active IP Right Cessation
- 1998-06-25 AP APAP/P/1998/001281A patent/AP1526A/en active
- 1998-06-26 PE PE1998000572A patent/PE88699A1/en not_active Application Discontinuation
- 1998-06-29 UY UY25067A patent/UY25067A1/en not_active IP Right Cessation
- 1998-06-29 MY MYPI98002948A patent/MY129175A/en unknown
- 1998-06-29 AR ARP980103148A patent/AR015919A1/en not_active Application Discontinuation
- 1998-06-30 DZ DZ980156A patent/DZ2546A1/en active
- 1998-06-30 TN TNTNSN98125A patent/TNSN98125A1/en unknown
- 1998-06-30 PA PA19988454401A patent/PA8454401A1/en unknown
- 1998-07-01 HR HR980379A patent/HRP980379B1/en not_active IP Right Cessation
- 1998-07-01 CO CO98037140A patent/CO4940402A1/en unknown
-
1999
- 1999-11-23 IS IS5265A patent/IS5265A/en unknown
- 1999-11-23 BG BG103915A patent/BG103915A/en unknown
- 1999-12-23 OA OA9900305A patent/OA11245A/en unknown
- 1999-12-28 NO NO996518A patent/NO996518L/en not_active Application Discontinuation
-
2000
- 2000-09-19 HK HK00105878A patent/HK1026630A1/en not_active IP Right Cessation
-
2006
- 2006-01-03 AR ARP060100016A patent/AR065827A2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2290966A1 (en) | Sertraline salts and sustained-release dosage forms of sertraline | |
EP2338482A3 (en) | Methods for treating neuropsychiatric disorders | |
CA2427815A1 (en) | Controlled release hydrocodone formulations | |
CA2251197A1 (en) | The use of mmp-13 selective inhibitors for the treatment of osteoarthritis and other mmp-mediated disorders | |
CA2355854A1 (en) | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations | |
CA2126611A1 (en) | Opiod Formulations Having Extended Controlled Release | |
AU7196096A (en) | Long-lasting release Nifedipine preparation | |
BG102259A (en) | Compostions with controlled paroxetine release | |
AU5861499A (en) | Agitation-independent pharmaceutical multiple unit retard preparations and method for the production thereof | |
HU9502843D0 (en) | Pharmaceutical composition | |
CA2342634A1 (en) | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative | |
EP1666041A3 (en) | Xanthine derivatives for treating neurodegenerative disorders | |
CA2198005A1 (en) | Pyrazolo[3,4-g]quinoxaline compounds which inhibit pdgf receptor protein tyrosine kinase | |
IL133442A0 (en) | Controlled release pharmaceutical preparation with ace inhibitor as active agent | |
CA2282279A1 (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions | |
PT1121109E (en) | BIPHASIC FORMULATION CONTAINING TRAMADOL | |
AP2002002662A0 (en) | Sertraline salts and sustained-release dosage forms of sertraline | |
TH43680A (en) | Chertaline salt and sertraline-delayed use patterns | |
CA2099667A1 (en) | Agent for treating hepatic diseases | |
ECSP982571A (en) | SERTRALINA SALTS AND SERTRALINA SUSTAINED RELEASE DOSAGE FORMS | |
SE9501773D0 (en) | New use | |
YU20050413A (en) | Controlled release oxycodone compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |